Loading…

415 A phase I study evaluating the safety profile and pharmacokinetics of CS-1008 (Tigatuzumab), humanized monoclonal antibody targeting death receptor 5 (DR5), in Japanese patients with advanced solid tumours

Saved in:

Bibliographic Details
Published in:	European journal of cancer supplements 2010, Vol.8 (7), p.132-132
Main Authors:	Nokihara, H, Yamamoto, N, Yamada, Y, Asahina, H, Shibata, T, Seki, Y, Tamura, Y, Honda, K, Misawa, S, Tamura, T
Format:	Article
Language:	English
Subjects:	Hematology, Oncology and Palliative Medicine
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!